{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:51:14Z","timestamp":1744213874793},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS R 12\/16"],"award-info":[{"award-number":["DJCLS R 12\/16"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.canlet.2016.08.007","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T07:58:25Z","timestamp":1470988705000},"page":"296-304","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model"],"prefix":"10.1016","volume":"381","author":[{"given":"Tobias","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"B\u00f6tticher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela A.E.","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Mier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Exner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artjom","family":"Wischnjow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludger","family":"Grosse-Hovest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Strumberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann-Josef","family":"Gr\u00f6ne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gottfried","family":"Brem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.08.007_bib0010","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrd1413","article-title":"Antibody-targeted radiation cancer therapy","volume":"3","author":"Milenic","year":"2004","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.canlet.2016.08.007_bib0015","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0020","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0025","first-page":"967","article-title":"Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I","volume":"42","author":"Stein","year":"2001","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.canlet.2016.08.007_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nucmedbio.2005.01.003","article-title":"177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo","volume":"32","author":"Michel","year":"2005","journal-title":"Nucl. Med. Biol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0035","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00259-009-1120-2","article-title":"In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study","volume":"36","author":"Forrer","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.canlet.2016.08.007_bib0040","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.112.115170","article-title":"Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I\/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas","volume":"54","author":"Forrer","year":"2013","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.canlet.2016.08.007_bib0045","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2014.112110","article-title":"Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed\/refractory, aggressive non-Hodgkin lymphoma","volume":"99","author":"Witzig","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2016.08.007_bib0050","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","article-title":"Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab","volume":"112","author":"Gopal","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.08.007_bib0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2967\/jnumed.108.058602","article-title":"Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma","volume":"50","author":"Sharkey","year":"2009","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.canlet.2016.08.007_bib0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40259-013-0016-7","article-title":"Targeting CD22 in B-cell malignancies: current status and clinical outlook","volume":"27","author":"Sullivan-Chang","year":"2013","journal-title":"Biodrugs"},{"key":"10.1016\/j.canlet.2016.08.007_bib0065","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin's lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00259-015-3175-6","article-title":"High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab","volume":"43","author":"Weber","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.canlet.2016.08.007_bib0075","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","article-title":"\u201cDiabodies\u201d: small bivalent and bispecific antibody fragments","volume":"90","author":"Holliger","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2016.08.007_bib0080","first-page":"814s","article-title":"Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors","volume":"50","author":"Jain","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0085","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jss.2011.03.065","article-title":"Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer","volume":"170","author":"Girgis","year":"2011","journal-title":"J. Surg. Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2191-219X-4-13","article-title":"Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)","volume":"4","author":"Kampmeier","year":"2014","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11307-011-0500-8","article-title":"An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors","volume":"14","author":"McCabe","year":"2012","journal-title":"Mol. Imaging Biol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0105","first-page":"1962","article-title":"124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice","volume":"44","author":"Sundaresan","year":"2003","journal-title":"J. Nucl. Med"},{"key":"10.1016\/j.canlet.2016.08.007_bib0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/protein\/gzp081","article-title":"ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)","volume":"23","author":"Olafsen","year":"2010","journal-title":"Protein Eng. Des. Sel"},{"key":"10.1016\/j.canlet.2016.08.007_bib0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view","volume":"34","author":"Boswell","year":"2007","journal-title":"Nucl. Med. Biol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0120","first-page":"287a","article-title":"Patient-specific dosing of Bexxa is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors","volume":"20","author":"Fehrenbacher","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0125","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1158\/0008-5472.CAN-03-2382","article-title":"A single treatment of yttrium-90-labeled CHX-A\u2033-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice","volume":"64","author":"Adams","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1021\/bc100464e","article-title":"Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging","volume":"22","author":"Li","year":"2011","journal-title":"Bioconjug. Chem"},{"key":"10.1016\/j.canlet.2016.08.007_bib0135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bbrc.2005.03.215","article-title":"Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein","volume":"331","author":"Krauss","year":"2005","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.canlet.2016.08.007_bib0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0014-5793(98)01728-1","article-title":"Human nerve growth factor beta (hNGF-beta): mammary gland specific expression and production in transgenic rabbits","volume":"444","author":"Coulibaly","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.canlet.2016.08.007_bib0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1023\/A:1008831028620","article-title":"Stable production of human insulin-like growth factor 1 (IGF-1) in the milk of hemi- and homozygous transgenic rabbits over several generations","volume":"7","author":"Zinovieva","year":"1998","journal-title":"Transgenic Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0150","doi-asserted-by":"crossref","first-page":"561814","DOI":"10.1155\/2015\/561814","article-title":"A humanized anti-CD22-onconase antibody-drug conjugate mediates highly potent destruction of targeted tumor cells","volume":"2015","author":"Weber","year":"2015","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.canlet.2016.08.007_bib0155","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.nucmedbio.2015.06.006","article-title":"Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy","volume":"42","author":"Haller","year":"2015","journal-title":"Nucl. Med. Biol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/ndt\/gfn626","article-title":"Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine","volume":"24","author":"Song","year":"2009","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.canlet.2016.08.007_bib0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/protein\/gzg096","article-title":"Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment","volume":"16","author":"Krauss","year":"2003","journal-title":"Protein Eng"},{"key":"10.1016\/j.canlet.2016.08.007_bib0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0163-7258(03)00069-X","article-title":"Transgenic rabbits as therapeutic protein bioreactors and human disease models","volume":"99","author":"Fan","year":"2003","journal-title":"Pharmacol. Ther"},{"key":"10.1016\/j.canlet.2016.08.007_bib0175","doi-asserted-by":"crossref","first-page":"580463","DOI":"10.1155\/2013\/580463","article-title":"Expression systems and species used for transgenic animal bioreactors","volume":"2013","author":"Wang","year":"2013","journal-title":"Biomed Res. Int"},{"key":"10.1016\/j.canlet.2016.08.007_bib0180","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0185","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0969-8051(00)00103-7","article-title":"Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules","volume":"27","author":"Adams","year":"2000","journal-title":"Nucl. Med. Biol"},{"key":"10.1016\/j.canlet.2016.08.007_bib0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/bc0502614","article-title":"Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody","volume":"17","author":"Li","year":"2006","journal-title":"Bioconjug. Chem"},{"key":"10.1016\/j.canlet.2016.08.007_bib0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev"},{"key":"10.1016\/j.canlet.2016.08.007_bib0200","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1073\/pnas.88.4.1394","article-title":"scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair","volume":"88","author":"Biedermann","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2016.08.007_bib0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2249.2008.03753.x","article-title":"Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment","volume":"154","author":"Pearson","year":"2008","journal-title":"Clin. Exp. Immunol"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516304645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516304645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T07:56:20Z","timestamp":1536479780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516304645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0304383516304645"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.08.007","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}